首页> 外国专利> Composition for predicting the risk of thiopurine-induced leukopenia, comprising a single nucleotide polymorphism marker in NUDT15 gene

Composition for predicting the risk of thiopurine-induced leukopenia, comprising a single nucleotide polymorphism marker in NUDT15 gene

机译:用于预测硫嘌呤诱导的白细胞减少症风险的组合物,其在NUDT15基因中包含单核苷酸多态性标记

摘要

The present invention relates to a composition for predicting the onset risk of thiopurine-induced leukopenia comprising a single nucleotide polymorphism marker in the NUDT15 gene, and specifically includes a single nucleotide polymorphism marker in the NUDT15 gene. The present invention relates to a risk prediction composition, risk prediction kit and risk prediction method for thiopurine-induced leukopenia in patients with Crohn's disease, ulcerative colitis, leukemia or organ transplantation. According to the present invention, patients with Crohn's disease, ulcerative colitis, leukemia or organ transplantation can be quickly and quickly classified into patients who are highly sensitive to leukopenia occurring during the thiopurine treatment process. Can perform patient customized treatment efficiently.
机译:本发明涉及用于预测硫嘌呤诱导的白细胞减少症发作风险的组合物,其在NUDT15基因中包含单核苷酸多态性标记,并且具体地在NUDT15基因中包含单核苷酸多态性标记。本发明涉及在克罗恩氏病,溃疡性结肠炎,白血病或器官移植患者中硫嘌呤诱导的白细胞减少症的风险预测组合物,风险预测试剂盒和风险预测方法。根据本发明,患有克罗恩氏病,溃疡性结肠炎,白血病或器官移植的患者可以迅速地分类为对在硫嘌呤治疗过程中发生的白细胞减少症高度敏感的患者。可以有效地执行患者定制的治疗。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号